Press "Enter" to skip to content

A two-dose version of the Johnson & Johnson vaccine provides comparable protection to a two-dose regimen of Moderna’s or Pfizer’s, the company says

A two-dose version of Johnson & Johnson’s coronavirus vaccine provides 94% protection against symptomatic infection, the company said Tuesday — making a two-dose regimen of J&J’s Janssen vaccine comparable to a two-dose regimen of Moderna’s or Pfizer’s.

A two-dose version of Johnson & Johnson’s coronavirus vaccine provides 94% protection against symptomatic infection, the company said Tuesday — making a two-dose regimen of J&J’s Janssen vaccine comparable to a two-dose regimen of Moderna’s or Pfizer’s.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *